Intended for UK healthcare professionals
Soprobec contains beclometasone dipropionate in a pressurised inhalation solution.
Prophylactic management of mild, moderate, or severe asthma in adults or children. See SmPC for full details.
Adults: Usual starting dose is 200 mcg twice daily. In severe cases this may be increased up to 600-800 mcg daily, reduced when the patient's asthma has stabilised. Total daily dose should be administered as 2-4 divided doses.
Children: Usual starting dose is 100 mcg twice daily. Depending on asthma severity, this may be increased up to 400 mcg administered in 2-4 divided doses.
The VolumaticTM spacer device must always be used for:
Soprobec comes in four strengths:50 mcg, 100 mcg, 200 mcg and 250 mcg
it’s just like Clenil®…3
An equivalent user experience to Clenil®1-4
Soprobec inhalers have equivalent design and functioning to Clenil® Modulite® with equivalence in specifications for:3,4
The cost of Soprobec is 25% lower than the equivalent Clenil® pack and strength.6
What could this cost saving representfor you?
Think Soprobec for all pMDI beclometasone dipropionate prescriptions
Prescribe Soprobec by brand to ensure:
Your patients get the device prescribed
You get the full cost savings for your practice
Your health economy gets the full cost savings
Glenmark Pharma offers support for commissioners and payers in the various NHS health economies.
Glenmark can provide bespoke financial savings estimates for your local health economy. To find out how much your health authority could save, click on the link below to arrange an appointment.
The Glenmark planned approach – commitment to supply readiness
We are committed to ensuring Soprobec is available to order from the moment usage is agreed:
Local health economy (LHE) agrees to move from Clenil® to Soprobec
Glenmark HO informed by representative
Glenmark HO alerts wholesalers
Wholesalers ensure they stock sufficient supply of Soprobec for LHE
Soprobec supply -ready to meet your needs
When you prescribe Soprobec by brand, your patients have access to clear information and support to ensure they take their medication correctly.
Patient tear-off pad, allowing healthcare professionals to give patients a sheet with information about Soprobec and how to use their inhaler. Click here to request more information.
The Soprobec dedicated patient website containsinformation and support for
The Soprobec dedicated patient website contains information and support for patients who have been prescribed Soprobec, with guidance on how to use their inhaler, FAQs and links to trusted websites. Click here to view.
Clenil® is a registered trademark of Chiesi Ltd. VolumaticTM is a trademark of GlaxoSmithKline UK Ltd.
PIP codes: Soprobec 50 mcg/actuation - 4098620, Soprobec 100 mcg/actuation- 4098638, Soprobec 200 mcg/actuation - 4098646, Soprobec 250 mcg/actuation - 4098653.
© 2019 Glenmark Pharma Ltd. All rights reserved. Date of preparation: May 2019 PP-UK-SOP-0015
By clicking this link, you are leaving the Soprobec website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.
If you wish to continue, please click ‘Continue’, otherwise click ‘Stay on page.’
